Basu Sandip, Houseni M, Bural G, Chamroonat W, Udupa J, Mishra S, Alavi Abass
Division of Nuclear Medicine, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia 19104, USA.
Mol Imaging Biol. 2007 Nov-Dec;9(6):361-5. doi: 10.1007/s11307-007-0112-5.
The aim of this study was to introduce a new concept for accurate measurement of the global metabolic activity of the red marrow by combining segmented volumetric data from structural imaging techniques such as magnetic resonance imaging (MRI) and quantitative metabolic information provided by functional modalities such as positron emission tomography (PET).
Imaging studies from five subjects who had undergone both MRI and 2-deoxy-2-[F-18]fluoro-D-glucose(FDG)-PET were selected for this analysis to test the feasibility of this approach. In none of the subjects, there were any marrow abnormalities as determined either by the MRI or by FDG-PET studies. The mean blood glucose level was 96+/-25 mg/dl. The first step was to calculate vertebral volume at L1, L3, and L5 from the available MRI studies. The red and yellow marrows were then segmented within the lumbar vertebrae using the 3DVIEWNIX software system from which the respective volumes were also calculated for each. This also allowed calculating the bone volume in each of the vertebral bodies examined. By employing the standard techniques, the mean of the maximum standardized uptake values (mean SUVmax) for the bone marrow were calculated in L1, L3 and L5 of the lumbar spine, and then global red marrow activity was calculated using the following approach: (1) Whole vertebral metabolic activity (WVMA)=vertebral volume x mean SUVmax of the entire marrow, (2) whole vertebral metabolic activity for yellow marrow (WVMAYM)=yellow marrow volume x mean SUVmax of fat (obtained from measurements of subcutaneous fat), (3) whole vertebral metabolic activity for red marrow (WVMARM)=WVMA-WVMAYM; and finally, (4) SUVmax for pure red marrow=whole vertebral metabolic activity for red marrow (WVMARM)/red marrow volume (obtained from the segmentation data).
The mean volume of the lumbar vertebral body was 15.6+/-1.4 cm3, the bone marrow mean SUVmax was 1.5+/-0.3, and the MVP for the lumbar vertebral body was 23.4+/-5.9. The mean volume of the yellow marrow in the lumbar vertebral body was 7.7+/-1.1 cm3, the yellow marrow mean SUVmax was estimated to be 0.38+/-0.1 and the MVP for the yellow marrow in the lumbar vertebral body was 2.9+/-0.9. The mean volume of the red marrow in lumbar vertebral body was 7.9+/-1.1 cm3, the red marrow mean SUVmax was estimated to be 2.6+/-0.6, and the MVP for the red marrow in the lumbar vertebral body was 20.5+/-5.9.
Estimation of the individual component of the bone marrow is plausible using medical image segmentation with combined structure-function approach. This can have potential research and clinical applications concerning the study of global metabolic activity of the individual component and diagnosis of benign and malignant bone marrow disorders.
本研究的目的是引入一种新概念,通过结合来自结构成像技术(如磁共振成像(MRI))的分割体积数据和功能模态(如正电子发射断层扫描(PET))提供的定量代谢信息,准确测量红骨髓的整体代谢活性。
选择5名同时接受了MRI和2-脱氧-2-[F-18]氟-D-葡萄糖(FDG)-PET检查的受试者的成像研究进行此分析,以测试该方法的可行性。在所有受试者中,MRI或FDG-PET研究均未发现任何骨髓异常。平均血糖水平为96±25mg/dl。第一步是根据可用的MRI研究计算L1、L3和L5椎体的体积。然后使用3DVIEWNIX软件系统在腰椎内分割红骨髓和黄骨髓,并分别计算它们的体积。这也使得能够计算每个检查椎体的骨体积。通过采用标准技术,计算腰椎L1、L3和L5骨髓的最大标准化摄取值(平均SUVmax)的平均值,然后使用以下方法计算整体红骨髓活性:(1)全椎体代谢活性(WVMA)=椎体体积×整个骨髓的平均SUVmax,(2)黄骨髓的全椎体代谢活性(WVMAYM)=黄骨髓体积×脂肪平均SUVmax(通过测量皮下脂肪获得),(3)红骨髓的全椎体代谢活性(WVMARM)=WVMA-WVMAYM;最后,(4)纯红骨髓的SUVmax=红骨髓的全椎体代谢活性(WVMARM)/红骨髓体积(从分割数据获得)。
腰椎椎体的平均体积为15.6±1.4cm³,骨髓平均SUVmax为1.5±0.3,腰椎椎体的MVP为23.4±5.9。腰椎椎体内黄骨髓的平均体积为7.7±1.1cm³,黄骨髓平均SUVmax估计为0.38±0.1,腰椎椎体内黄骨髓的MVP为2.9±0.9。腰椎椎体内红骨髓的平均体积为7.9±1.1cm³,红骨髓平均SUVmax估计为2.6±0.6,腰椎椎体内红骨髓的MVP为20.5±5.9。
使用结构-功能联合的医学图像分割来估计骨髓的各个成分是可行的。这在个体成分的整体代谢活性研究以及良性和恶性骨髓疾病的诊断方面可能具有潜在的研究和临床应用价值。